Article Text

other Versions

Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma
  1. Jasmine H Francis1,
  2. Y Pierre Gobin2,
  3. Scott E Brodie3,
  4. Brian P Marr1,
  5. Ira J Dunkel4,
  6. David H Abramson1
  1. 1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  2. 2Service of Interventional Neuroradiology, Weill Cornell Medical College of New York Presbyterian Hospital, New York, New York, USA
  3. 3Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, USA
  4. 4Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  1. Correspondence to Dr David H Abramson, Chief, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, 70 East 66th Street, New York, NY 10021, USA; abramsod{at}

Statistics from

We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye.


Three children with bilateral retinoblastoma (all with Reese–Ellsworth group IVa in one eye and 2b in one fellow eye and 5a in two fellow eyes; International Classification, …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.